Bank of Montreal Can bought a new position in shares of CareDx Inc (NASDAQ:CDNA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 17,806 shares of the company’s stock, valued at approximately $130,000. Bank of Montreal Can owned approximately 0.06% of CareDx as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Cambridge Investment Research Advisors Inc. acquired a new position in shares of CareDx during the 3rd quarter worth approximately $106,000. Perkins Capital Management Inc. acquired a new position in shares of CareDx during the 3rd quarter worth approximately $513,000. Thompson Davis & CO. Inc. grew its position in shares of CareDx by 3,294.9% during the 3rd quarter. Thompson Davis & CO. Inc. now owns 203,692 shares of the company’s stock worth $754,000 after purchasing an additional 197,692 shares in the last quarter. Private Wealth Partners LLC grew its position in shares of CareDx by 2,250.0% during the 3rd quarter. Private Wealth Partners LLC now owns 235,000 shares of the company’s stock worth $869,000 after purchasing an additional 225,000 shares in the last quarter. Finally, Royce & Associates LP grew its position in shares of CareDx by 8.1% during the 3rd quarter. Royce & Associates LP now owns 792,787 shares of the company’s stock worth $2,933,000 after purchasing an additional 59,500 shares in the last quarter. Hedge funds and other institutional investors own 52.35% of the company’s stock.
Shares of CareDx Inc (NASDAQ CDNA) opened at $5.75 on Wednesday. The company has a current ratio of 0.55, a quick ratio of 0.35 and a debt-to-equity ratio of -124.53. CareDx Inc has a 52-week low of $0.76 and a 52-week high of $7.98.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.